- Home
- TVTX
as 05-30-2025 12:43pm EST
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 1.7B | IPO Year: | N/A |
| Target Price: | $33.31 | AVG Volume (30 days): | 1.9M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.78 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.49 - $25.29 | Next Earning Date: | 05-01-2025 |
| Revenue: | $273,533,000 | Revenue Growth: | 75.65% |
| Revenue Growth (this year): | 74.41% | Revenue Growth (next year): | 48.90% |
Stock Insider Trading Activity of Travere Therapeutics Inc. (TVTX)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dube Eric M | TVTX | CHIEF EXECUTIVE OFFICER | May 2 '25 | Sell | $21.05 | 18,924 | $398,350.20 | 419,173 | |
| REED ELIZABETH E | TVTX | Chief Legal Officer and GC | May 2 '25 | Sell | $21.05 | 4,920 | $103,566.00 | 89,482 | |
| Heerma Peter | TVTX | CHIEF COMMERCIAL OFFICER | May 2 '25 | Sell | $21.05 | 1,771 | $37,279.55 | 128,215 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | May 2 '25 | Sell | $21.05 | 1,784 | $37,553.20 | 93,126 | |
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Apr 11 '25 | Sell | $13.14 | 48 | $630.94 | 93,126 |
Latest Travere Therapeutics Inc. News
TVTX Breaking Stock News: Dive into TVTX Ticker-Specific Updates for Smart Investing
PR Newswire
7 days ago
England's NICE recommends FILSPARI® (sparsentan) as a treatment option for IgA nephropathy
Business Wire
15 days ago
Travere Therapeutics Announces FDA Acceptance of sNDA for FILSPARI® (sparsentan) in FSGS
GlobeNewswire
17 days ago
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results
Business Wire
18 days ago
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire
23 days ago
Travere Therapeutics to Participate at Upcoming Investor Conferences
Simply Wall St.
a month ago
Analysts Have Made A Financial Statement On Travere Therapeutics, Inc.'s (NASDAQ:TVTX) First-Quarter Report
Business Wire
a month ago
Travere Therapeutics Reports First Quarter 2025 Financial Results
Business Wire
a month ago
Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA Nephropathy
Compare TVTX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "TVTX Travere Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.